Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Autor: Pignata, S, Scambia, G, Katsaros, D, Gallo, C, Pujade Lauraine, E, De Placido, S, Bologna, A, Weber, B, Raspagliesi, F, Panici, Pb, Cormio, G, Sorio, R, Cavazzini, Mg, Ferrandina, G, Breda, E, Murgia, V, Sacco, C, Cinieri, S, Salutari, V, Ricci, C, Pisano, C, Greggi, S, Lauria, R, Lorusso, D, Marchetti, C, Selvaggi, L, Signoriello, S, Piccirillo, Mc, DI MAIO, Massimo, Perrone, F, Multicentre Italian Trials in Ovarian cancer, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein, Mario Negri Gynecologic Oncology, European Network of Gynaecological Oncological Trial Groups, Gynecologic Cancer InterGroup Investigators

Background: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule combined with carboplatin every 3 weeks prolonged progression-free survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35e0b7d8280f4cac191f209083620cb9
http://hdl.handle.net/10807/72293

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Autor: DU BOIS, A, Quinn, M, Thigpen, T, Vermorken, J, AVALL LUNDQVIST, E, Bookman, M, Bowtell, D, Brady, M, Casado, A, Cervantes, A, Eisenhauer, E, Friedlaender, M, Fujiwara, K, Grenman, S, Guastalla, Jp, Harper, P, Hogberg, T, Kaye, S, Kitchener, H, Kristensen, G, Mannel, R, Meier, W, Miller, B, Neijt, Jp, Oza, A, Ozols, R, Parmar, M, Pecorelli, Sergio, Pfisterer, J, Poveda, A, Provencher, D, PUJADE LAURAINE, E, Randall, M, Rochon, J, Rustin, G, Sagae, S, Stehman, F, Stuart, G, Trimble, E, Vasey, P, Vergote, I, Verheijen, R, Wagner, U, GYNECOLOGIC CANCER INTERGROUP, Ago, Ovar, Anzgog, Eortc, Geico, Gineco, Gog, Jgog, Mrcncri, Ncic, Ctg, Nci, Us, Nsgo, Rtog, Sgctg, Igcs, ORGANIZATIONAL TEAM OF THE TWO PRIOR INTERNATIONAL OCCC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3662::d525d5fdabcf368cfb095280fa9f224f
http://hdl.handle.net/11379/20160

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

Autor: Sehouli J; Gynecology with Center for Oncological Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany jalid.sehouli@charite.de.; North-Eastern German Society of Gynaecological Oncology (NOGGO eV), Berlin, Germany., Boer J; North-Eastern German Society of Gynaecological Oncology (NOGGO eV), Berlin, Germany., Brand AH; Westmead Hospital, Westmead, New South Wales, Australia.; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Oza AM; Medical Oncology & Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., O'Donnell J; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Bennett K; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Glaspool R; Beatson West of Scotland Cancer Centre, Glasgow, UK., Lee CK; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia., Ethier JL; Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Harter P; Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.; AGO Study Group, Wiesbaden, Germany., Seebacher-Shariat V; AGO Austria, Innsbruck, Austria.; Medical University of Vienna, Vienna, Austria., Chang TC; Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.; Chang Gung University, Taoyuan, Taiwan., Cohen PA; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, Australia., van Gorp T; Gynaecological Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium., Chavez-Blanco A; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada., Welch S; Department of Oncology, Western University Schulich School of Medicine & Dentistry, London, Ontario, Canada., Hranovska H; National Academy of Medical Sciences of Ukraine, Kiiv, Ukraine., O'Toole S; Cancer Trials Ireland, Dublin, Ireland., Lok CAR; Department of Gynaecologic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands., Madariaga A; 12 de Octubre University Hospital, Madrid, Comunidad de Madrid, Spain.; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Rauh-Hain JA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Perez Fidalgo A; Medical Oncology, Hospital Clinico Universitario, Valencia, Spain., Tan D; National University Cancer Institute, Singapore., Michels J; Gustave Roussy, Villejuif, Île-de-France, France.; Université Paris-Saclay, Villejuif, Île-de-France, France., Pothuri B; NYU Langone Health Perlmutter Cancer Center, New York, New York, USA., Fujiwara N; Department of Palliative Medicine and Advanced Clinical Oncology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Minato-city, Tokyo, Japan.; Gynecologic Oncology Trial and Investigation Consortium (GOTIC), Moroyama, Japan., Rosengarten O; Medical Gyneco-Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel., Nishio H; Department of Obstetrics and Gynecology, Keio Univesity School of Medicine, Tokyo, Japan.; Japanese Gynecologic Oncology Group (JGOG), Tokyo, Japan., Kim SI; Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea (the Republic of)., Mukopadhyay A; Kolkata Gynecological Oncology Trials and Translational Research Group (KolGOTrg), Kolkata, India., Piovano E; Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy., Cecere SC; Dep. of Experimental Uro-Gynecological Oncology, National Cancer Institute Institute for Hospitalization and Care Scientific Foundation Pascale, Naples, Italy., Kohn EC; Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA., Mukherjee U; GynaeOncology Trials Group UK (GCG UK), London, UK., Nasser S; Department of Gynecology with Center of Oncological Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany.; Pan-Arabian Research Society of Gynecological Oncology, Berlin, Germany., Lindemann K; Department of gynecological oncology, Oslo University Hospital, Oslo, Norway.; Nordic Society of Gynaecological Oncology (NSGO), Copenhagen, Denmark., Croke J; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Chen X; Tongji University Dongfang Hospital, Shanghai, Shanghai, China., Geissler F; Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland.; Swiss GO Trial Group, Basel, Switzerland., Bookman MA; The Gynecologic Cancer InterGroup, Kingston, Ontario, Canada.; Kaiser Permanente Northern California, Oakland, California, USA.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Nov 04; Vol. 34 (11), pp. 1677-1684. Date of Electronic Publication: 2024 Nov 04.

Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium.

Autor: Phan NTH; Danang Oncology Hospital, Danang, Vietnam., Tran QT; Danang Oncology Hospital, Danang, Vietnam., Nguyen NPT; Danang Oncology Hospital, Danang, Vietnam., Nguyen HT; Danang Oncology Hospital, Danang, Vietnam., Tran LDN; Ho Chi Minh Oncology Hospital, Ho Chi Minh City, Vietnam., Pham VC; K Hospital, Hanoi, Vietnam., Bennett K; Gynecologic Cancer InterGroup Cervix Cancer Research Network, Kingston, Ontario, Canada., Chavez-Blanco A; Latin America and Cervix Cancer Research Network sites, Mexico City, Mexico., Plante M; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Laval University, Quebec City, Canada., Suh DH; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea., Nout R; Gynecologic Cancer InterGroup (GCIG) Dutch Gynecologic Oncology Group (DGOG), Amsterdam, The Netherlands.; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Tan DSP; Gynecologic Cancer InterGroup (GCIG) Gynecologic Cancer Group Singapore (GCGS), Singapore.; Department of Medical Oncology, National University Cancer Institute, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Cancer Science Institute, National University of Singapore, Singapore.; National University Centre for Cancer Research (N2CR), National University of Singapore, Singapore. David_sp_tan@nuhs.edu.sg.

Publikováno v: Journal of gynecologic oncology [J Gynecol Oncol] 2023 Sep; Vol. 34 (5), pp. e88.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.

Autor: Bagnoli M; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. marina.bagnoli@istitutotumori.mi.it., Shi TY; Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. tyshi80@163.com., Gourley C; University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh EH4 2XU, UK. Charlie.Gourley@ed.ac.uk., Speiser P; Department of Gynaecologic Oncology, Medical University Vienna, General Hospital Vienna, 1090 Wien, Austria. pspeis54@gmail.com., Reuss A; Coordinating Center for Clinical Trials, at the Philipps-University of Marburg, 35043 Marburg, Germany. alexander.reuss@kks.uni-marburg.de., Nijman HW; Department of Obstetrics & Gynecology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands. h.w.nijman@umcg.nl., Creutzberg CL; Department of Radiation Oncology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. c.l.creutzberg@lumc.nl., Scholl S; Department of Drug Development and Innovation, Institut Curie, 75005 Paris, France. suzy.scholl@curie.fr., Negrouk A; European Organisation for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium. anastassia.negrouk@eortc.org., Brady MF; Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY 14203, USA. brady@gogstats.org., Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama 1397-1, Japan. koseih@gmail.com., Oda K; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8654, Japan. katsutoshi-tky@umin.ac.jp., McNeish IA; Division of Cancer, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. i.mcneish@imperial.ac.uk., Kohn EC; Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD 20852, USA. kohne@mail.nih.gov., Oza AM; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada. Amit.Oza@uhn.ca., MacKay H; Division of Medical Oncology, University of Toronto/Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada. helen.mackay@sunnybrook.ca., Millan D; Department of Pathology, Queen Elizabeth University Hospital, Glasgow G51 4TR, UK. david.millan59@btinternet.com., Bennett K; Gynecologic Cancer InterGroup, Operations, Kingston, ON K7K-7A6, Canada. gcigopsasst@gmail.com., Scott C; Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. scottc@wehi.edu.au., Mezzanzanica D; Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. delia.mezzanzanica@istitutotumori.mi.it.

Publikováno v: Cells [Cells] 2019 Feb 26; Vol. 8 (3). Date of Electronic Publication: 2019 Feb 26.